Avmapki Fakzynja Co-Pack is a combination therapy comprising avutometinib, a MEK inhibitor, and defactinib, a FAK inhibitor, provided in a co-packaged format for the treatment of specific cancers. ⭕ Indication: ➡️ Primarily indicated for the treatment of patients with low-grade serous ovarian cancer (LGSOC), particularly those with RAS pathway mutations who have received prior systemic therapy. It may be used in other investigational settings as well. ⭕ Mechanism of Action: ➡️ Avutometinib inhibits MEK1/2, blocking the MAPK pathway which is often hyperactivated in cancers with RAS/RAF mutations. Defactinib targets focal adhesion kinase (FAK), a protein involved in tumor cell survival, proliferation, and resistance to therapy. ⭕ Therapeutic Benefit: ➡️ The combination aims to overcome resistance mechanisms in RAS-mutant tumors by dual inhibition of MEK and FAK pathways, potentially improving clinical outcomes in patients with hard-to-treat cancers. Become a part of our dynamic LinkedIn community to stay updated on the latest trends in publishing, research, and pharmaceutical webinars. Gain access to exclusive insights and opportunities that can enhance your career. Follow us today and embark on the SPSR journey with us! https://www.linkedin.com/company/spsr2010